Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
14JUN

Mykor's £4m grows panels from mushrooms

3 min read
16:35UTC

Bristol's Mykor raised £4m on 27 May to grow building panels from mycelium, with £337m in orders signed before the first panel ships. Demand proven ahead of production, the opposite of most cleantech risk.

← Back to London startup raises Britain's own AI modelJump to analysis ↓
TechnologyDeveloping
Key takeaway

Mykor booked £337m in orders before shipping a single panel, inverting the usual cleantech risk.

Mykor, a Bristol company, raised £4m on Wednesday 27 May, led by the Clean Growth Fund with co-investors The FSE Group and Green Angel Ventures plus an Innovate UK grant, taking total funding to £7.5m 1. Mykor grows structural insulated panels from engineered mycelium, the root structure of fungi, and agricultural waste. The panels, branded MykoSIP, carry 60% less embodied carbon than conventional insulation and a Euroclass B fire rating, the European standard for limited combustibility. Co-founders Olivia Page and Valentina Dipietro are Forbes 30 Under 30 honourees, and the company employs 22 staff.

The number that separates Mykor from most cleantech is the order book: £337m in pre-production commercial agreements signed with UK and European contractors 2. That figure matters because it is signed before the first panel ships, which inverts the usual cleantech risk. Most materials startups burn capital proving a market exists; Mykor has booked demand and now needs to build supply. The £4m funds production capacity against contracts already in hand, not a hope that buyers will appear.

A Bristol firm with 22 staff is a different animal from a London AI raise, and that is the point. The regional, non-Golden-Triangle deeptech tier is alive, echoing earlier rounds outside the south-east such as Rivan's £25m for a synthetic-gas plant in Wiltshire and the regional life-sciences manufacturing sites the Life Sciences Innovative Manufacturing Fund backed in April . These companies raise from cleantech specialists and grant bodies, not the funds chasing the next billion-dollar AI label, which is exactly why the aggregate capital figures pass them by while the work goes on.

Deep Analysis

In plain English

Most building insulation, the material packed into walls to keep heat in, comes from mineral wool (rock or glass fibres) or plastic foam. Both require energy-intensive industrial processes to make, which creates carbon emissions before the building even opens. This is called 'embodied carbon'. Mykor grows its panels from mycelium, the root-like network of a fungus, combined with agricultural waste like straw or husks. The mycelium binds the waste material together into a rigid panel. Growing the panels uses far less energy than manufacturing conventional insulation, so the embodied carbon is roughly 60% lower. The fire rating matters because buildings have to pass fire safety tests; Mykor's panels have achieved a Euroclass B rating, which means they meet the standard required for most commercial and residential construction. The £337m in pre-production agreements means large building contractors have already committed to buy these panels once production scales up, before the first production line reaches full volume.

Deep Analysis
Root Causes

UK construction's embodied-carbon problem persists for two reasons operating at different speeds. In the short term, procurement departments at large contractors price on upfront material cost rather than whole-life carbon cost, because planning and building regulations do not yet require embodied-carbon reporting.

Mykor's pre-production agreements are an early signal that the 2025 Future Homes Standard consultation, which proposed mandatory whole-life carbon assessments, is already shifting contractor behaviour ahead of legal requirement.

In the medium term, the clean-build materials market lacks a domestic institutional anchor comparable to Longwall for deeptech. The Clean Growth Fund, which led Mykor's round, is the primary UK-domiciled cleantech early-stage vehicle at this cheque size. Innovate UK grant co-funding supplements equity but does not replace it. The result is a concentration of supply: if Clean Growth Fund's follow-on appetite changes, Mykor's next round has limited alternative domestic leads.

What could happen next?
  • Opportunity

    The £337m pre-production pipeline, if it converts at standard construction industry lead times of 2-4 years, would take Mykor from a £7.5m funded startup to a company with material revenue comparable to its total funding raise, without requiring additional equity.

  • Risk

    Installer-skills gaps for biogenic panel systems could delay conversion of the pre-production pipeline; the Ecovative precedent shows 4-6 year lags between signing and volume delivery for novel materials.

Sources:Tech Funding News
Mentions:The FSE Group →Innovate UK →Life Sciences Innovative Manufacturing Fund →Wiltshire →Rivan →Forbes →Dell →London →Mykor →
First Reported In

Update #6 · Orbital's $50m has no UK lead

Tech Funding News· 29 May 2026
Read original →
Causes and effects
Caused by
Rivan raises £25m for Europe's biggest SNG plant
Rivan's £25m cleantech raise in Wiltshire (ID:2702) showed regional, non-Golden-Triangle deeptech capital continues to flow outside AI; Mykor's £4m Bristol raise echoes that pattern.
Occurred 20 Apr 2026
Read story →
This Event
Mykor's £4m grows panels from mushrooms
A Bristol cleantech raise with orders booked pre-production shows the regional deeptech tier the AI mega-rounds skip is alive and selling.
Led to
Gigaton lands $26m for plant autonomy
UK climate hard-tech finding capital at earlier stages (Mykor £4m in May) preceded Gigaton raising at a more advanced revenue stage.
Occurred 3 Jun 2026
Read story →
Different Perspectives
Fubon Financial
Fubon Financial
Fubon Financial joined Humanoid's Series A on 21 July as a minority financial investor alongside Schaeffler and Bosch, who also hold the customer and manufacturer roles. A pure-play investor from Taipei is pricing a London robot maker on terms two German industrial groups effectively set.
NATO Innovation Fund
NATO Innovation Fund
The Fund joined Greenjets' £30m Series A on 21 July alongside NSSIF, betting on ducted electric propulsion's civil market to fund a technology with an obvious defence application. It is backing a company that took twenty-one years to reach this stage, on the expectation that certification-cycle timelines reward patient capital over a quick return.
Prime Movers Lab
Prime Movers Lab
Prime Movers Lab led Humanoid's Series A on 21 July as the round's only pure financial investor, sharing the cap table with two co-investors who are also the anchor customer and the factory. That leaves the fund's usual arm's-length pricing role diluted by partners with a direct commercial stake in the valuation holding up.
Bosch and Schaeffler
Bosch and Schaeffler
Schaeffler signed what Humanoid calls the industry's largest publicly announced commercial agreement, while Bosch took equity and became contract manufacturer, filling capacity a shrinking combustion supply chain freed. Neither company has disclosed a unit count or an invoice, so their public commitment stops well short of Forbes' 100,000-unit projection.
UK founders raising seed through Series A
UK founders raising seed through Series A
A London robotics founder raised $152m this week against a signed industrial customer and a reserved factory, while a Cornwall founder more typically draws a £25,000 loan from a regional fund manager. Both call it British venture funding, but one route runs through Bosch's production line and the other through diligence built for businesses too small for any VC's attention.
EQT
EQT
EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.